SEARCH:   Advanced

Blood, 15 July 2007, Vol. 110, No. 2, pp. 501-508. Prepublished online as a Blood First Edition Paper on March 29, 2007; DOI 10.1182/blood-2007-01-066522. This Article Full Text (PDF) Supplemental Figure All Versions of this Article: blood-2007-01-066522v1 110/2/501    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sakamoto, N. Articles by Rosenberg, A. S. Search for Related Content PubMed PubMed Citation Articles by Sakamoto, N. Articles by Rosenberg, A. S. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted January 5, 2007 Accepted March 24, 2007 Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in FCS in mice and humans Norihisa Sakamoto, Kazuhide Tsuji, Linda M. Muul, Ann M. Lawler, Emanuel F. Petricoin, Fabio Candotti, Julia A. Metcalf, Jorge A. Tavel, H. Clifford Lane, Walter J. Urba, Bernard A. Fox, Ajit Varki, Joan K. Lunney, and Amy S. Rosenberg* Division of Therapeutic Proteins, CDER, U.S. Food and Drug Administration, Bethesda, MD, United States Department of Dermatology, Okayama University Graduate School of Medicine and Dentistry and Pharmaceutical Sciences, Okayama, Japan Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, United States Transgenic Mouse Facility and Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, United States Center for Applied Proteomics and Molecular Medicine, Dept of Molecular & Microbiology, George Mason University, Manassas, VA, United States Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A Chiles Research Institute, Portland Medical Center, Portland, OR, United States Glycobiology Research and Training Center, and Depts of Medicine and Cellular & Molecular Medicine, University of California, San Diego, CA, United States Animal Parasitic Diseases Laboratory, Agricultural Research Service, United States Department of Agriculture, Beltsville, MD, United States * Corresponding author; email: amy.rosenberg{at}fda.gov. Recent studies have demonstrated that cell populations intended for therapeutic purposes that are cultured in heterologous animal products can acquire xenoantigens, potentially limiting their utility. In investigations of the immune response to murine embryonic stem (ES) cells, we found that a strong antibody response was generated after the second infusion. Both polyclonal and monoclonal antibody responses, derived from immunized mice, were found to be specific for bovine apolipoprotein B-100 which binds to abundant low density lipoprotein receptor on the cell surface and is internalized. Here we have shown that in the majority of patients administered three different types of cell-based therapies utilizing cells grown in FCS containing media, an antibody response to bovine apoB-100 develops following the second infusion and is the dominant specificity. The known and potential clinical effects of such antibodies are discussed. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Hisamatsu-Sakamoto, N. Sakamoto, and A. S. Rosenberg Embryonic Stem Cells Cultured in Serum-Free Medium Acquire Bovine Apolipoprotein B-100 from Feeder Cell Layers and Serum Replacement Medium Stem Cells, January 1, 2008; 26(1): 72 - 78. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020